Basic Doxepin Information

• INN (International Nonproprietary Name): not specified
• Brand Names Available In Canada (English): not specified
• ATC Code: not specified
• Forms & Dosages: not specified
• Manufacturers In Canada (English): not specified
• Registration Status In Canada (English): not specified
• OTC / Rx Classification: not specified

Latest Research Highlights

What new studies tell us about doxepin and why patients ask about sleepy nights and safety.

Recent randomized trials from 2022 to 2025 show that low‑dose doxepin, typically 3–6 mg at bedtime and sold as a Silenor‑style product in some jurisdictions, produces consistent small‑to‑moderate improvements in sleep maintenance compared with placebo.

Higher therapeutic doses of doxepin remain effective for depressive and anxiety disorders but carry larger anticholinergic and cardiac risks, especially in older adults.

Canadian pharmacoepidemiology reports have highlighted that tricyclic antidepressants contribute to an elevated anticholinergic burden and are associated with higher fall and hip‑fracture rates among seniors in routine practice.

Case series from Canadian tertiary centres have flagged prolonged QT intervals and conduction delays when doxepin is combined with other QT‑prolonging agents.

Systematic reviews reinforce that topical doxepin has a limited role for pruritus, with mixed evidence for meaningful benefit over standard topical therapies.

Canadian clinicians are increasingly emphasising non‑drug sleep measures, such as cognitive behavioural therapy for insomnia, before prescribing low‑dose doxepin for sleep maintenance.

Geriatric Safety Signals:

Canadian data highlight increased falls and anticholinergic burden in seniors taking TCAs including doxepin.

Older patients started on higher antidepressant doses had higher rates of ECG abnormalities when co‑prescribed QT‑prolonging drugs.

Clinical practice in Canada now commonly weighs non‑pharmacologic sleep strategies before low‑dose doxepin is started.

Clinical Effectiveness In Canada

Patients ask whether doxepin works and whether provincial plans will cover it.

Health Canada authorizations list doxepin hydrochloride for depressive disorders and related anxiety states.

Low‑dose formulations for insomnia, similar to Silenor, may have separate regulatory entries and product monographs; verify the specific product DIN before dispensing.

In real‑world Canadian primary‑care data, doxepin performs similarly to other tricyclic antidepressants for mood disorders but is less well tolerated than many SSRIs due to anticholinergic side effects.

Coverage varies by province; generic doxepin often appears on public drug lists while branded low‑dose sleep products sometimes require special or private coverage.

When doxepin is used for insomnia in Canada, pharmacists typically check for contraindications such as severe hepatic impairment and recent monoamine oxidase inhibitor use.

Pharmacists also counsel patients to treat insomnia with doxepin for weeks rather than indefinitely and to re‑assess ongoing need.

Indications And Expanded Uses

Patients frequently ask what doxepin is approved for and what it can be used off‑label for.

Approved indications in Canada include depressive disorders and associated anxiety states.

Low‑dose doxepin formulations are indicated for sleep maintenance insomnia where a product specifically authorised for that indication exists.

Common off‑label uses in Canada, supported by variable evidence, are neuropathic pain, chronic urticaria when topical options are trialled, and refractory insomnia after non‑drug measures fail.

• Approved indications: depressive disorders; anxiety states; low‑dose insomnia where authorised.
• Evidence‑grade off‑label uses: neuropathic pain (moderate evidence), topical for chronic itch (limited/mixed), refractory insomnia (clinical practice use).
• Monitoring needs per indication: mood monitoring for depression, liver function if hepatic disease suspected, ECG monitoring for cardiac risk factors.

Off‑label use should be documented with a clear rationale and informed consent, and specialist care is commonly involved for pain, sleep or dermatology indications.

Shared‑decision materials should be culturally adapted and bilingual for Indigenous and remote communities where specialist access may be limited.

Composition And Brand Landscape

People wondering "what's actually in these tablets" need a quick overview of formulations and brands in Canada.

The active moiety is doxepin hydrochloride, a tricyclic antidepressant with antihistaminic and anticholinergic properties.

Available formulations include tablets and capsules in multiple strengths and low‑dose film‑coated tablets commonly in 3 mg and 6 mg for insomnia use.

Historically recognised brand names include Sinequan for higher‑dose doxepin, and Silenor for low‑dose insomnia formulations where marketed.

Generic doxepin hydrochloride is widely available in Canada with DINs assigned to specific presentations depending on manufacturer and strength.

Generic vs Brand Pros/Cons:

Generics are generally lower cost and more widely covered by provincial formularies.

Branded low‑dose options may be preferred by some prescribers for insomnia but can be more expensive or require special authorisation.

Contraindications And Special Precautions

Patients often want to know who should avoid doxepin and what to watch for.

Absolute contraindications include recent MAOI use within 14 days, known hypersensitivity to doxepin, the acute recovery phase after myocardial infarction, and severe uncontrolled narrow‑angle glaucoma or urinary retention.

Special precautions recommended by Health Canada and standard clinical practice include obtaining a baseline ECG in older adults or those with cardiac disease, reducing doses in hepatic impairment, and avoiding doxepin where anticholinergic burden is already high.

ECG

Baseline and periodic ECG in patients over 65 or with cardiac disease.

Liver Function

Dose reduction or alternative agent in marked hepatic impairment.

Fall Risk

Assess and mitigate fall risk in seniors due to sedation and orthostatic effects.

High‑risk Canadian subgroups include seniors with polypharmacy, patients with active substance use or alcohol use that potentiates sedation, and remote populations where emergency services are distant.

Dosage Guidelines

Many patients ask "how much do I take" and "what about older relatives".

For adult depressive disorders, initiation commonly starts around 75 mg per day in divided doses, then titrated up to 150–300 mg per day as tolerated and clinically indicated.

For insomnia using low‑dose formulations, typical dosing is 3 mg or 6 mg once nightly at bedtime.

In elderly patients clinicians follow a "start low and go slow" approach, with many starting at 10–25 mg per day for mood symptoms or choosing low‑dose insomnia options to minimise anticholinergic load.

Marked hepatic impairment generally requires large dose reductions or selection of an alternative agent.

Tapering should be gradual; reduce slowly over 2–4 weeks to avoid withdrawal symptoms and consult the prescriber before stopping abruptly.

Interactions Overview

People worry about mixing doxepin with other medicines and alcohol.

Major interactions include MAOIs, which are contraindicated due to serotonin syndrome risk and other serious reactions.

Other important interactions are with QT‑prolonging drugs that can add cardiac risk, strong CYP2D6 and CYP1A2 inhibitors or inducers that alter doxepin levels, and concurrent antidepressants like SSRIs or SNRIs that can increase side‑effect burden.

Antihistamines and other anticholinergic agents produce additive dry mouth, constipation and risk of delirium, particularly in older adults.

Alcohol and other CNS depressants increase sedation and hepatic strain and should be avoided while taking doxepin.

Contraindicated

MAOIs within 14 days; combinations causing marked QT prolongation.

Use With Caution

Strong CYP inhibitors/inducers; SSRIs; other sedatives or anticholinergics.

Monitor

ECG when combined with QT‑prolonging drugs; dose adjustments with hepatic impairment.

Community pharmacists routinely screen for these interactions and counsel patients when doxepin, doxepin hydrochloride or branded products like Sinequan are dispensed.

Cultural Perceptions And Patient Habits

Patients often describe doxepin as an "older" drug that still works but comes with more side effects.

Canadian online forums and support groups frequently mention sedation, weight change and anticholinergic effects as common patient concerns.

Urban patients tend to prefer SSRIs and cognitive therapies, while rural and remote patients may encounter TCAs more often because of cost and prescriber familiarity.

Bilingual materials and culturally tailored counselling are essential for Indigenous patients and communities with different health beliefs and higher comorbidity burdens.

Community pharmacists are often the first point of contact and offering printed bilingual fact sheets reduces misuse and improves adherence.

Availability And Pricing Patterns

Where patients can get doxepin and what it costs are common questions.

Generic doxepin is widely stocked at major Canadian chains such as Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs, as well as independent pharmacies across provinces.

Lower‑dose branded insomnia formulations are less consistently stocked and may need special ordering or prior authorisation under some provincial plans.

Many provincial formularies list generic doxepin under public plans, but coverage rules and prior‑authorisation requirements differ between Ontario Drug Benefit, BC PharmaCare and RAMQ.

In our online pharmacy, doxepin is available without a prescription, with discreet delivery to Canada (English) in 5–14 days.

Online Canadian‑licensed pharmacies verify DINs before dispensing and follow provincial teleprescribing protocols as required.

Cross‑border price comparisons sometimes show cheaper retail prices in the U.S., but importation rules and patient safety should be considered before purchasing abroad.

Comparable Medicines And Preferences

Patients and prescribers often ask what to try instead of doxepin.

For depression and anxiety, SSRIs such as sertraline and escitalopram and SNRIs such as venlafaxine are common first choices because of better tolerability for many patients.

For sleep, trazodone or mirtazapine are sometimes chosen as sedating alternatives depending on the patient's need for appetite or weight effects.

For neuropathic pain, amitriptyline and nortriptyline are other TCAs used clinically; nortriptyline tends to have a lower anticholinergic burden than doxepin.

Choosing an alternative is a balance of efficacy, tolerability, comorbidities and provincial coverage.

Frequently Asked Questions

Patients want short, practical answers they can act on.

• Is doxepin covered by public drug plans?
• Generic doxepin often appears on provincial formularies; check ODB, BC PharmaCare or RAMQ using the DIN for exact coverage rules.
• Can I drive while taking doxepin?
• Avoid driving until you know how doxepin affects you because drowsiness and impaired concentration are common.
• What if I miss a dose?
• Take as soon as you remember unless it is near the next dose; do not double doses.
• How quickly does doxepin work for depression?
• Antidepressant effects typically take 2–6 weeks; sedative effects may appear sooner.
• What should I do in an overdose?
• Seek immediate emergency care as doxepin overdose can be life‑threatening with cardiac arrhythmia or seizures.

Emergency Steps:

Call local emergency services or your provincial poison centre right away if overdose is suspected.

Guidelines For Proper Use

Pharmacists play a key role in safe dispensing and counselling for doxepin.

Before dispensing, verify DIN and the applicable Health Canada monograph for the product provided by the prescriber.

Screen for recent MAOI use and co‑prescribed QT‑risk medications, and counsel patients about sedation, anticholinergic effects, driving and alcohol avoidance.

Provide clear bilingual written instructions where possible and document counselling encounters, especially in remote communities.

• Baseline ECG recommended for patients over 65 or with cardiac history.
• Periodic review of side effects and fall‑risk assessment in seniors.
• Consider LFTs if hepatic disease is suspected.
• Taper over 2–4 weeks or longer to reduce withdrawal symptoms; coordinate tapering with the prescriber.

Provincial tips include checking ODB/BC PharmaCare/RAMQ for coverage and applying for special authorisation when branded low‑dose formulations are required.

Delivery Across Canada (English)